Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Masimo (NASDAQ:MASI) Share Price

News stories about Masimo (NASDAQ:MASI) have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Masimo earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.3164298370563 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the news articles that may have effected Accern Sentiment’s analysis:

A number of research firms recently commented on MASI. Zacks Investment Research lowered shares of Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. BidaskClub downgraded shares of Masimo from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $108.00 price target on shares of Masimo in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. Masimo presently has an average rating of “Hold” and an average price target of $97.17.

Masimo (NASDAQ:MASI) opened at $86.10 on Thursday. Masimo has a fifty-two week low of $69.57 and a fifty-two week high of $104.71. The stock has a market cap of $4,450.00, a price-to-earnings ratio of 13.65, a price-to-earnings-growth ratio of 3.41 and a beta of 0.72.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.53 by $0.17. The firm had revenue of $193.69 million for the quarter, compared to analysts’ expectations of $189.01 million. Masimo had a return on equity of 22.17% and a net margin of 45.83%. The company’s revenue was up 15.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.52 earnings per share. analysts predict that Masimo will post 2.95 EPS for the current year.

In other Masimo news, EVP Yongsam Lee sold 10,000 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $88.17, for a total value of $881,700.00. Following the completion of the transaction, the executive vice president now owns 75,018 shares in the company, valued at $6,614,337.06. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 63,074 shares of company stock valued at $5,618,945. 13.10% of the stock is owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/11/masimo-masi-receives-coverage-optimism-rating-of-0-17.html.

Masimo Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Insider Buying and Selling by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply